TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04451187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
Study: NCT02761213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Description: Oral sulfate solution (OSS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-L PEG/Asc
Description: Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
Study: NCT02427295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin (Octreotide Acetate)
Description: For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection.
Study: NCT01485484

Intervention type: DEVICE
Intervention: Optic imaging use near-infrared trans-illumination methods
Description: Optic imaging use near-infrared trans-illumination methods
Study: NCT02404519

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Menaquinone-7
Description: 1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet without MK-7 taken orally every day during 1 year
Study: NCT00254293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
Study: NCT00300274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
Study: NCT01778127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Measurement of physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Measurement of physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Measurement of physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Website
Description: Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Website
Description: Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
Study: NCT00300274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Corticosteroids standard dose.
Study: NCT00719459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: Venofer 20 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose
Description: Iron sucrose 20 mg/mL
Study: NCT02419261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgical repair of the anterior cruciate ligament

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgical repair of the anterior cruciate ligament
Study: NCT01778127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
Study: NCT01206127

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative positioning: Sitting up
Description: Patients in this group should be sitting up in a chair 2 hours postoperative
Study: NCT04934904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
Study: NCT01731041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg
Description: Patients will receive 180 mg of ticagrelor
Study: NCT01968122

Intervention type: DEVICE
Intervention: intravascular stent therapy
Description: Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
Study: NCT01731041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Patients will receive 90 mg of ticagrelor
Study: NCT03185156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
Study: NCT03802032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Gel
Description: topical lidocaine gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KY jelly
Description: topical KY jelly
Study: NCT01778127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
Study: NCT01724125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personal electronic medical record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personal electronic medical record
Study: NCT01643759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
Study: NCT00389103

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVA (smallpox vaccine)
Description: 0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
Study: NCT01341379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-carbamylglutamate
Description: N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
Study: NCT02527551

Intervention type: OTHER
Group type: OTHER
Intervention: Massage
Description: 6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
Study: NCT02403830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a 0.9% sodium chloride iv injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: After methylnaltrexone, patients will receive 5-mg intravenous morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: After methylnaltrexone, patients will receive 5-mg intravenous morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After morphine administration, patients will receive a 180-mg ticagrelor loading dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: After morphine administration, patients will receive a 180-mg ticagrelor loading dose
Study: NCT04007055

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of care screening for HPR
Description: HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
Study: NCT04004078

Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
Study: NCT01517347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT00642980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Study: NCT04364737

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma
Description: SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
Study: NCT03937661

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Autologous PRP intra ovarian infusion
Study: NCT00642980

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
Study: NCT04423146

Intervention type: OTHER
Intervention: The evocation of reproducible motor evoked potential according to the different BIS levels
Description: The evocation of reproducible motor evoked potential and the actual value of amplitude and latency at different BIS levels (40 - 60) will be monitored.
Study: NCT04147910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Single oral dose of KW-6356
Study: NCT03315884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
Description: Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
Description: Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
Study: NCT02494999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: 0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
Study: NCT03106142

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Academic detailing visit arm
Description: General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
Study: NCT01475123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: 15mg per day
Study: NCT04432688

Intervention type: DRUG
Intervention: Lurasidone HCl
Description: This is a non-interventional, observational study
Study: NCT04468698

Intervention type: OTHER
Intervention: Peritoneum insufflation
Description: Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.
Study: NCT03601780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local wound infiltration plus usual care
Description: local wound infiltration plus usual care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: usual care only
Description: usual care only
Study: NCT01815008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81 mg daily
Study: NCT01474707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group one
Description: Group 1 will view the knowledge-based video only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group two
Description: Group two will view the motivational video only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group three
Description: Group three will view both knowledge-based and motivational videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group four
Description: Group four will view the printed educational pamphlet and will not view either video
Study: NCT01365208

Intervention type: DRUG
Intervention: Chemotherapy
Description: platinum-based chemotherapy
Study: NCT03047746

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACs
Description: Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACs
Description: Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique

Intervention type: DEVICE
Group type: OTHER
Intervention: CliniMACs
Description: Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
Study: NCT02983617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously
Study: NCT03221023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Hydrochloride
Description: Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Individuals in the control arm will receive intrawound saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Individuals in the control arm will receive intrawound saline solution
Study: NCT00831272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 50mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04187664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Monitoring
Description: Nursing and medical staff will monitor patients vital signs and clinical deterioration triggers twice as often as in previous ward care.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin testing
Description: High-risk patients will have their high-sensitivity cardiac troponin tested preoperatively and daily for the first 48h postoperatively
Study: NCT00596310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT
Description: Screening CT